Zytiga gains traction, Provenge stands still
June 26 2012
Dendreon's prostate cancer drug Provenge may be a first-line treatment, but a recent poll by Kantar Health shows that competitor ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.